Silexion Therapeutics Corp (SLXN) News
Follow Silexion Therapeutics Corp (SLXN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Silexion Therapeutics Corp. (SLXN) Doses First Patient in Phase 2/3 SIL204 Trial
Silexion Therapeutics Corp. dosed the first patient in its multinational Phase 2/3 trial of SIL204 plus chemotherapy in locally advanced pancreatic cancer, starting at Tel Aviv Sourasky Medical Center, with expansion sit
GEOPOLITICS | Sep 30, 2026, 12:01 PM UTC
L
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancerIntegrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor
NEWS | Sep 30, 2026, 12:01 PM UTC
L
Silexion Therapeutics doses first patient in Phase 2/3 trial
Silexion Therapeutics said the first patient was successfully dosed in its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.
EQUITY | Sep 30, 2026, 12:00 PM UTC
H
Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of FingerMotion Inc (NASDAQ: FNGR ) rose sharply in pre-market trading after the company announced it had entered into a definitive Share Purchase Agreement to acquire 100% of Newbit Technology Inc. Under the agre
LIVE | Sep 30, 2026, 09:32 AM UTC
L
Silexion Therapeutics Raises $0.84M Through Warrant Inducement, Hires H.C. Wainwright as Agent
Silexion Therapeutics executed a warrant inducement to raise approximately $0.84 million in gross proceeds by reducing the exercise price of 3,216,928 existing Series E warrants to $0.2603 per share and agreeing to issue
NEWS | Sep 29, 2026, 02:34 PM UTC
L
Silexion Therapeutics Corp. (SLXN) Raises ~$0.84M From Warrant Exercises
Silexion entered agreements for immediate exercise of certain Series E warrants at $0.2603, for expected gross proceeds of $0.84M, and will issue new Series F and G warrants of equal amount. It also cut the exercise pric
NEWS | Sep 29, 2026, 12:12 PM UTC
L
Silexion Therapeutics Announces Exercise of Warrants
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. NASDAQ:SLXN (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-drive
NEWS | Sep 29, 2026, 12:09 PM UTC
L
Silexion Reports SIL204 Uses Native Lipoproteins for Cellular Uptake, Supports Systemic Phase 2/3 Plan
Silexion reports positive preclinical data showing SIL204 leverages endogenous serum lipids for dose-dependent KRAS knockdown.Key Highlights:Original SEC Filing: Silexion Therapeutics Corp [ SLXN ] - 8-K - Sep. 28, 2026T
REGULATION | Sep 28, 2026, 12:54 PM UTC
L
Silexion Therapeutics Corp. (SLXN) Validates Native Lipid Uptake Mechanism for SIL204
Silexion Therapeutics reported translational data showing SIL204 uses circulating lipoproteins for cellular entry and KRAS knockdown in vitro, supporting systemic administration in its Phase 2/3 program.Material DetailsC
NEWS | Sep 28, 2026, 12:38 PM UTC
L
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdownFindings validate that physiological lipoprotein levels are sufficient f
NEWS | Sep 28, 2026, 12:38 PM UTC
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
Silexion Therapeutics to participate in September 2026 industry conferences
Silexion Therapeutics announced management will participate in September 2026 Industry and Investor Conferences. The company is a clinical-stage biotechnology focused on RNA interference (RNAi) therapies for KRAS-driven
EQUITY | Sep 09, 2026, 01:03 PM UTC
L
SLXN - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
SLXN - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
EQUITY | Sep 09, 2026, 01:00 PM UTC
L
Silexion Therapeutics reports Q2 2026 financial results, business update
Silexion Therapeutics (SLXN) reports second quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 12:45 PM UTC
H
US Inflation Rate Slows To 3.4% In July
The US Consumer Price Index rose 3.4% year-over-year in July, down from June's 3.5% increase
MACRO | Aug 12, 2026, 01:42 PM UTC
M
Multiple Companies Announce Public Offerings
Several companies announce public offerings and private placements of various securities
EQUITY | Aug 12, 2026, 09:25 AM UTC
L
SLXN Launches $2.5M Public Offering
SLXN announces $2.5 million public offering at $0.65 per share
EQUITY | Aug 12, 2026, 12:24 AM UTC
L
SLXN Prices $2.5 Million Public Offering
Silexion Therapeutics announces pricing of $2.5 million public offering
EQUITY | Aug 12, 2026, 12:01 AM UTC
H
Silexion Therapeutics Reports Positive Preclinical Findings
Silexion reports positive preclinical findings for SIL204
EQUITY | Aug 04, 2026, 01:15 PM UTC
H
SLXN Initiates Phase 2/3 Trial
SLXN starts phase 2/3 trial for SIL204
EQUITY | Jul 29, 2026, 11:00 AM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
SLXN Initiates Phase 2/3 Trial
Silexion Therapeutics receives approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
EQUITY | Jun 23, 2026, 12:42 PM UTC